In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Ipamorelin | Synthetic analog Hexarelin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 110 | 1,112 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 1 (1 in people) | 21 (13 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 21 more mentions it but does not test it | None registered | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Ipamorelin | Hexarelin |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 293242 | 369 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 22 Oct 2026).
| Pituitary hormonesEndocrine and hormones | 66 | 6464 |
|---|
| Receptor activity and mechanismPharmacology | 312 | 105123801 |
|---|
| PharmacokineticsPharmacology | 1376 | 5052916 |
|---|
| Bone and jointMusculoskeletal | 1515 | 286193 |
|---|
| Body weightMetabolic and weight | 99 | 1129 |
|---|
| Glycemic controlEndocrine and hormones | 22 | 153111 |
|---|
| Appetite and food intakeMetabolic and weight | 33 | 15114 |
|---|
| Sex hormones and fertilityReproductive and sexual health | 1111 | 615 |
|---|
| Adverse eventsWhole body | 11 | 22 |
|---|
| Gastrointestinal protectionGastrointestinal | 22 | 88 |
|---|
| Exercise and physical functionMusculoskeletal | 11 | 615 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Ipamorelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
Hexarelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Ipamorelin | Hexarelin |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in mu/l | No randomized trial result 29 results from other study designs. | 6.8 mU/l Peak GH · hexarelin 0.5 microgram/kg during SS50 Dose studied: 0.5 microgram/kgn = 121997 |
| Pituitary hormonesEndocrine and hormonesCompared as: value in the arm that got the peptide, in pg/ml | No randomized trial result 6 results from other study designs. | 30.3 pg/ml ACTH peak Dose studied: 2.0 microg/kgn = 62001 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 87.5% Any treatment-emergent adverse event Placebo: 94.8% Dose studied: 0.03-mg/kg twice dailypostoperative day 1 to 7 or hospital dischargen = 1142014 | No randomized trial result |
No randomized trial result
29 results from other study designs.
6.8 mU/l
Peak GH · hexarelin 0.5 microgram/kg during SS50
Dose studied: 0.5 microgram/kgn = 121997
2 results from other study designs.
No randomized trial result
6 results from other study designs.
30.3 pg/ml
ACTH peak
Dose studied: 2.0 microg/kgn = 62001
87.5%
Any treatment-emergent adverse event
Placebo: 94.8%
Dose studied: 0.03-mg/kg twice dailypostoperative day 1 to 7 or hospital dischargen = 1142014
No randomized trial result
2 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)
Helsinn Therapeutics (U.S.), Inc320 participantsApr 2011 to May 2014
Gastrointestinal Dysmotility
Helsinn Therapeutics (U.S.), Inc117 participantsApr 2008 to Dec 2009
Ileus
1 more mentions it but does not test it. They only measure it or name it in their text.
No registered trial that tests Hexarelin found in ClinicalTrials.gov.